The AHSN Network has supported many innovators to help advance our health and care system. Find out more about successful innovations supported by the NHS.
REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) is a facilitated evidence based cardiac rehabilitation (CR) and self-management programme for use at home. It comprises the ‘Heart Failure Manual’, a Relaxation CD, a choice of exercise (walking programme or a chair-based DVD) a ‘Progress Tracker’ for patients, and a ‘Family and Friends Resource’ for caregivers.
The Oxford AHSN Accelerator programme, in collaboration with BioCity and regional partners from the NHS, industry and research within the Thames Valley, offers a launchpad for entrepreneurs and their ventures to move from idea to market. MetaGuideX won a place on the intensive eight-week programme and pitched to investors on the final day of the Accelerator programme in November 2020.
The Oxford AHSN already enjoys a very productive relationship with the global healthcare company Johnson & Johnson (J&J). J&J is one of the largest employers linked to healthcare in our region with its headquarters in High Wycombe.
FeNO (Fractional exhaled Nitric Oxide) testing alongside the recommended NICE diagnostic tests, will help enable more accurate diagnosis of asthma. Over 120,000 patients a year, 30% of the asthma population, are wrongly diagnosed and given inappropriate medication. Our project will look to reduce the use of steroids and improve diagnosis, enabling correct adjustments or the right medication to be prescribed. FeNO is indicative of the severity of airway inflammation.
Less than 50% of severe asthma patients have eosinophil-driven disease (Wenzel2005) and Biologics are designed to control the number of eosinophil cells (Asthma UK). Only 10.8% of eligible severe asthma patients have access to biologic medicines today in the UK.Increasing the use of biologics appropriately would reduce use of Oral corticosteroids (OCS), associated with negative side effects, and exacerbations, causing 75,000 annual UK hospital admissions, each costing £1500.
PINCER is the Pharmacist-led Information technology iNtervention for the reduction of Clinically important ERrors in medicines management.
The improved accuracy of the high sensitivity test compared to the standard troponin test allows testing of troponin concentration and type (T or I) at 1-hour and/or 3-hours post ED presentation. This innovation adoption in both technology and pathway will greatly improve patient care and efficiency at ED, enabling patients to be sent home secure in the knowledge that a heart attack has not occurred while keeping beds free in ED.
The UK multiple sclerosis (MS) population is expected to increase annually by 2.4%1. Cladribine offers an orally administered option for highly active relapsing-remitting MS, avoiding the need for infusions, and requires less frequent dosing and monitoring compared to other therapies.
Multiple Individuals can pass through a door only SECONDS apart. Surfaceskins Alcohol Gel Door Push Pads & Pull Handles are engineered by infection control experts to KILL germs in SECONDS & protect EVERY door user. Over 5 years of development & validation in NHS Laboratories, hospital & schools to help provide ultimate touch protection with two studies in the JOHI [Journal of Hospital Infection]. For more information please visit www.surfaceskins.comOr email: adamw@surfaceskins.com or info@surfaceskins.com
The HIN has been commissioned to support a drive to equip members and partners to offer the Covid Oximetry @home model. This comes as treatment of Covid-19 improves and evidence has shown that earlier detection of (silent) hypoxia at home could help further reduce mortality and morbidity.
The Health Innovation Network (HIN) has been commissioned to support a drive to equip members and partners to offer the Covid Oximetry @home model. This comes as treatment of Covid-19 improves and evidence has shown that earlier detection of (silent) hypoxia at home could help further reduce mortality and morbidity.
Covid-19 led to a rapid shift from face to face to remote consultations in mental health. What has this meant for service users and staff?
